ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 4,975 Shares

Key Points

• Thomas Andrew Rowland, SVP of ANI Pharmaceuticals, sold 4,975 shares at an average price of $85.71, resulting in a 10.87% decrease in his ownership.
• ANI Pharmaceuticals reported a strong quarterly earnings performance, with $1.80 EPS exceeding analysts' expectations of $1.42 and a 53.2% year-over-year revenue increase to $211.37 million.
• The stock has received various ratings, with an average rating of “Moderate Buy” and a consensus price target of $84.75 from analysts.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Thomas Andrew Rowland sold 4,975 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $85.71, for a total value of $426,407.25. Following the completion of the sale, the senior vice president directly owned 40,794 shares of the company's stock, valued at approximately $3,496,453.74. This trade represents a 10.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

ANI Pharmaceuticals Stock Performance

ANIP traded up $1.26 during trading on Thursday, reaching $90.00. The company's stock had a trading volume of 604,501 shares, compared to its average volume of 623,678. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $90.23. The company's fifty day moving average price is $67.34 and its 200-day moving average price is $64.62. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -116.88 and a beta of 0.61. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%. The company had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same quarter in the previous year, the company earned $1.02 EPS. The firm's revenue for the quarter was up 53.2% compared to the same quarter last year. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Hohimer Wealth Management LLC raised its holdings in ANI Pharmaceuticals by 5.2% during the first quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock worth $334,000 after purchasing an additional 247 shares during the last quarter. Legal & General Group Plc increased its stake in shares of ANI Pharmaceuticals by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 46,712 shares of the specialty pharmaceutical company's stock worth $3,048,000 after purchasing an additional 351 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of ANI Pharmaceuticals by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after purchasing an additional 364 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of ANI Pharmaceuticals by 10.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,368 shares of the specialty pharmaceutical company's stock worth $285,000 after purchasing an additional 396 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock worth $3,235,000 after purchasing an additional 423 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ANIP has been the topic of several recent research reports. Wall Street Zen cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. HC Wainwright restated a "buy" rating and issued a $93.00 price target (up previously from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Guggenheim restated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Truist Financial boosted their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research report on Monday. Finally, Piper Sandler restated an "overweight" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $84.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.